Immune linkages between inflammatory bowel disease and spondyloarthropathies

Current Opinion in Rheumatology

Volumn 14, Issue 4, 2002, Pages 342-347

  Baeten, Dominique ^a   De Keyser, Filip ^a   Mielants, Herman ^a   Veys, Eric M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL DNA; CD8 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; HLA B27 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RIBOSOME RNA; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULAR ADHESION PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENTERITIS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; SYNOVIUM; T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; INTESTINE MUCOSA; PATHOPHYSIOLOGY;

HUMAN; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; SPONDYLARTHROPATHIES; SYNOVIAL MEMBRANE; T-LYMPHOCYTES, CYTOTOXIC; HUMANS;

EID: 0035985810     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200207000-00002     Document Type: Review

References (67)

1. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis
2. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study
3. Modification of disease outcome in Salmonella-infected patients by HLA-B27
4. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats
5. Spondyloarthropathy is underestimated in inflammatory bowel disease: Prevalence and HLA-association
6. Musculoskeletal manifestations in inflammatory bowel disease
7. Subclinical sacroiliitis in inflammatory bowel disease: A clinical and follow-up study
8. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study
9. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease
10. Ileocolonoscopic findings in seronegative spondylarthropathies
11. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects
12. Long-term evolution of gut inflammation in patients with spondyloarthropathy
13. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint
14. Evidence of subclinical intestinal inflammation by 99m technetium leukocyte scintigraphy in patients with HLA-B27 positive juvenile onset active spondyloarthropathy
15. Clinical significance of abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondyloarthropathies
16. Focal upregulation of E-cadherin/catenin complex in inflamed bowel mucosa, but reduced expression in ulcer-associated cell lineage
17. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex
18. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease
19. Increased gut permeability in juvenile chronic arthritides: A multivariate analysis of the diagnostic parameters
20. Increased number of macrophages in non-inflamed colon of patients with spondyloarthropathy, a human model of early Crohn's disease
21. Chlamydia and Berrelia DNA in synovial fluid of patients with early undifferentiated oligoadhritis: Results of a prospective study
22. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis
23. Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloadhropathies
24. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis
25. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicentre, double-blind, randomized, placebo-controlled study
26. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without arthritis
27. Comparative study of the synovial histology in rheumatoid arthritis, spondyloadhropathy, and osteoadhritis: Influence of disease duration and activity
28. Immunohistological study of the entheses in spondyloarthropathies: Comparison in rheumatoid adhritis and osteoarthritis
29. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome
30. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy
31. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF-α
32. Low T cell production of TNF-α and IFNγ in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-306 gene polymorphism
33. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloadhropathies
34. Human leucocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules
35. Gut mucosal T cell lines from patients with ankylosing spondylitis are enriched with αEβ7 integrin
36. Enrichment of T cells carrying β7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis
37. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloadhropathy: Histologic findings in eight patients from an open-label pilot study
38. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy
39. Identification of HLA-B27-restricted peptides from the Chalmydia trachomatic proteome with possible relevance to HLA-B27-associated disease
40. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: Overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles
41. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry
42. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4+ T cells from humans infected with Chalmydia trachornatic
43. CD4+ and CD6+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins
44. The recognition of HLA-B27 by human CD4+ T lymphocytes
45. HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis
46. Human immunodeficiency virus associated spondyloarthropathy: Pathogenic insights based on imaging findings and response to highly active antiretroviral treatment
47. Colitis in HLA-B27/β2 microglobulin transgenic rats
48. Macrophages expressing the scavenger receptor CD163: A link between immune alterations of the gut and synovial inflammation in spondyloarthropathy
49. The porcine 2A10 antigen is homologous to human CD163 and related to macrophage differentiation
50. IL10,G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients
51. Inflammatory bowel disease: Lessons from the IL-10 genedeficient mouse
52. Expression of host defense scavenger receptors in spondyloarthropathy
53. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
54. A frameshift mutation in NOD2 asoociated with susceptibility to Crohn's disease
55. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
56. A short-term study of chimeric monoclonal antibody cAé to tumor necrosis factor-α for Crohn's disease
57. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on articular symptoms
58. Effects of a loading regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor-α (infliximab) in spondyloarthropathy: An open pilot study
59. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-α monoclonal antibody infliximab
60. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy
61. Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNFα antibody infliximab in a placebo controlled multicenter trial
62. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease
63. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families
64. Diagnostic value of anti-Saccharomyces cerevisiae and anti-neutrophil cyotplasmac autoantibodies in inflammatory bowel disease
65. Anti-saccharomyces cerevisiae antibodies in akylosing spondylitis
66. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
67. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease